Investigational New Drugs

, Volume 10, Issue 4, pp 331–335

Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma

  • Frank V. Fossella
  • Rodger J. Winn
  • Paul Y. Holoye
  • Becky Hallinan
  • Martin N. Raber
  • Karen Hoelzer
  • James A. Young
  • Joseph Readling
  • Barbara Bowers
  • Waun Ki Hong
Phase II Clinical Trials

DOI: 10.1007/BF00944191

Cite this article as:
Fossella, F.V., Winn, R.J., Holoye, P.Y. et al. Invest New Drugs (1992) 10: 331. doi:10.1007/BF00944191

Summary

We treated 34 chemotherapy-naive patients with stage IIIb or IV non-small cell lung cancer with trimetrexate 150–200 mg/m2 intravenously over 30 minutes every two weeks. Six of 31 evaluable patients (19%) achieved a partial response. The major toxic effects from this regimen were myelosuppression, nausea/vomiting, and skin rash. We conclude that this well-tolerated schedule of trimetrexate has significant activity as a single agent against non-small cell lung cancer.

Key words

trimetrexate non-small cell lung cancer phase II trial 

Copyright information

© Kluwer Academic Publishers 1992

Authors and Affiliations

  • Frank V. Fossella
    • 1
  • Rodger J. Winn
  • Paul Y. Holoye
    • 1
  • Becky Hallinan
    • 1
  • Martin N. Raber
    • 1
  • Karen Hoelzer
    • 2
  • James A. Young
    • 3
  • Joseph Readling
    • 4
  • Barbara Bowers
    • 5
  • Waun Ki Hong
    • 1
  1. 1.Department of Medical OncologyThe University of Texas M.D. Anderson Cancer CenterHouston
  2. 2.Central Illinois Community Clinical Oncology Program (CCOP)Springfield
  3. 3.St. Francis Hospital/Natalie Warren Bryant CCOPTulsa
  4. 4.Twin Tiers CCOPBinghamton
  5. 5.West Metro-Minneapolis CCOPSt. Louis ParkUSA

Personalised recommendations